Lantheus Holdings, Inc.

BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to LUTATHERA® (lutetium Lu 177 dotatate).

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per sha

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus' products through 2030.Halper Sadeh encourages Lantheus shareholders to click here to learn more about their.